• Moderna swung to a third-quarter 2026 net profit of $162 million from a year-earlier loss.
• Revenue climbed 29% year-over-year to $1.31 billion, driven primarily by higher international COVID vaccine sales.
• Research and development expenses fell 27% year-over-year to $583 million, primarily due to lower clinical development costs.
• Intismeran combined with KEYTRUDA reduced recurrence or death risk by 42% versus KEYTRUDA alone in a Phase 3 melanoma study.
• The 2026 revenue growth outlook rose to 15%-25% from up to 10% previously.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611060645ACCESSWRNAPR_____1247635) on November 06, 2026, and is solely responsible for the information contained therein.